NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL(TM) Platform

Stock Information for NeuBase Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuBase Therapeutics Inc.

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
NeuBase Therapeutics to Explore Strategic Alternatives
NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors(TM) are Non-Immunogenic, Opening the Door to Redosing
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.